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Pancreatic development depends on the transcription factor Pax6, which controls islet cell differentiation and hormone production. To
understand the regulation of Pax6 pancreatic expression, we have identified a minimal Pax6 pancreatic enhancer and show that it contains a
composite binding site for Meis and Pbx homeoproteins. We further show that Meis proteins are expressed during pancreatic development, and
together with Pbx, are able to form a synergistic binding complex on the Pax6 pancreatic enhancer. When tested in transgenic mice, both the Meis
and Pbx sites are essential for Pax6 pancreatic enhancer activity, and the composite site can be functionally replaced by a consensus Meis–Pbx
sequence. In addition, analysis of Pbx1 and Pbx2 knockout mice demonstrates that, during pancreatic islet formation, Pax6 expression becomes
dependent upon Pbx1 and Pbx2 function. As Meis homeoproteins have been previously demonstrated to regulate Pax6 expression during lens
development, these results suggest a conserved mechanism of Pax6 regulation by Meis homeoproteins in two different organs.
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Vertebrate pancreatic cells derive from a common pool of
pluripotent progenitors. A complex network of interacting
transcription factors, including the paired domain and homeo-
domain containing transcription factor Pax6, underlies endo-
crine cell differentiation during pancreatic development.
Several lines of evidence support the functional role of Pax6
in pancreatic development. In the Pax6 mutant, Sey1Neu, all
endocrine cell types are reduced in number (Sander et al., 1997).
In the Pax6−/− knockout, glucagon-producing α cells are absent
and islet structure is disrupted (St-Onge et al., 1997).
Interestingly, this is compensated for by a significant increase
in the number of ghrelin expressing ε cells (Heller et al., 2004;
Prado et al., 2004). Glucose intolerance and diabetes have also
been observed in patients with PAX6 mutations (Yasuda et al.,⁎ Corresponding author.
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doi:10.1016/j.ydbio.2006.06.0302002). The sensitivity of pancreatic development to Pax6 gene
dosage is further demonstrated by transgenic mice overexpres-
sing Pax6, which develop diabetes and pancreatic adenomas
(Yamaoka et al., 2000).
Pax6 is a key regulator of islet hormone gene expression.
The promoter regions of the genes encoding glucagon, insulin
and somatostatin all contain Pax6 binding sites, and Pax6 can
activate transcription of these genes in cell culture (Andersen et
al., 1999; Ritz-Laser et al., 1999; Sander et al., 1997). As a
consequence, hormone production is substantially reduced in
the Pax6 mutant pancreas, and mice with a pancreas specific
knockout of Pax6 die soon after birth from overt diabetes
(Ashery-Padan et al., 2004; Sander et al., 1997). Pax6 can also
interact with other transcription factors in the pancreas. For
example, the transactivation ability of Pax6 on the glucagon
promoter is significantly enhanced by its direct interaction with
Cdx-2/3 and Maf (Hussain and Habener, 1999; Planque et al.,
2001; Ritz-Laser et al., 1999). More recently, Pax6 binding to
Pax4 and Pdx1 control sequences has been demonstrated, and
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mice (Ritz-Laser et al., 2002; Samaras et al., 2002; Wang et al.,
2004). Thus, Pax6 also plays a direct role in the regulation of
key pancreatic regulators.
During pancreatic development, a number of transcription
factors are known to act earlier than Pax6. These include Hb9
and Pdx1 (also known as Ipf1, Idx-1 and Stf-1), two
homeodomain proteins expressed in the pre-pancreatic endo-
derm (Ahlgren et al., 1996; Guz et al., 1995; Harrison et al.,
1999; Li et al., 1999; Miller et al., 1994; Offield et al., 1996).
Loss of Hb9 expression blocks dorsal but not ventral pancreatic
bud formation from the endoderm (Harrison et al., 1999; Li et
al., 1999). Meanwhile, abrogation of Pdx1 results in an arrest of
pancreatic development at the bud stage (Ahlgren et al., 1996;
Jonsson et al., 1994; Offield et al., 1996). A conditional gene
inactivation experiment reveals that Pdx1 is required for the
differentiation of both islet and acinar cells in later development
(Ahlgren et al., 1998). Another pancreatic bud specific
transcription factor is P48 (also known as Ptf1a), which can
bias gut epithelium toward pancreatic instead of duodenal fates
(Kawaguchi et al., 2002; Krapp et al., 1998). The TALE (three
amino acid loop extension) family homeoprotein Pbx1 is a
known binding partner of Pdx1, and both exocrine and
endocrine cell differentiation are severely disrupted in the
Pbx1 mutant (Dutta et al., 2001; Kim et al., 2002; Peers et al.,
1995; Swift et al., 1998).
The first endocrine lineage specific gene is Neurogenin3
(Ngn3), which is only transiently expressed in the pancreatic
epithelium (Apelqvist et al., 1999; Jensen et al., 2000;
Schwitzgebel et al., 2000). Nevertheless, inactivation of Ngn3
results in a complete loss of endocrine cells (Gradwohl et al.,
2000). Conversely, ubiquitous expression of Ngn3 converts the
entire pancreas to an endocrine fate (Apelqvist et al., 1999;
Schwitzgebel et al., 2000). Expressed slightly later than Ngn3,
the LIM homeodomain protein Islet-1 is expressed in newly
differentiated endocrine cells, and its function is clearly
demonstrated by its mutant phenotype, which includes a failure
of all endocrine cells to differentiate (Ahlgren et al., 1997). At
the onset of Pax6 expression, other endocrine-cell-specific
transcription factors also appear in the pancreas. These include
NeuroD1, Nkx2.2, Pax4, Nkx6.1 and Brn4, all of which affect
endocrine cell subtype specification (Hussain et al., 2002; Naya
et al., 1997; Sander et al., 2000; Sosa-Pineda et al., 1997; Sussel
et al., 1998). Many of these genes are candidates to encode
direct regulators of Pax6 during pancreatic development.
In a recent study of vertebrate eye development, we
uncovered a role for the Meis family homeoproteins Meis1
and Meis2 in controlling Pax6 lens placode expression (Zhang
et al., 2002). In this role, Meis recognizes a conserved sequence
in the Pax6 lens placode enhancer and forms a multi-protein
complex with currently unknown co-factor(s) to directly
regulate Pax6 lens placodal expression. To search for direct
upstream regulators of Pax6 in the pancreas, we previously
identified a Pax6 pancreatic enhancer which resides on a
450 bp element 1.9 kb upstream of the Pax6 P0 promoter
(Zhang et al., 2003). In transgenic mice, this enhancer is
specifically active in the embryonic pancreas where itsexpression recapitulates endogenous Pax6 expression. In the
current study, we have further refined the Pax6 pancreatic
enhancer to a minimal 237 bp element. Biochemical studies
show that this enhancer contains an evolutionarily conserved
composite Meis–Pbx binding site, which exhibits distinct
binding activities for different Meis family members. By
transgenic analysis, we demonstrate that this Pax6 regulatory
sequence that binds Meis and Pbx is required for Pax6
pancreatic enhancer activity in vivo and that it can be replaced
by a consensus Meis–Pbx site. Finally, genetic deletion of Pbx1
and Pbx2 results in the down-regulation of Pax6 expression
during pancreatic development. Therefore, Pbx and Meis
homeoproteins collectively regulate Pax6 expression in the
pancreas.
Materials and methods
Transgenic constructs
All transgenic constructs were derived from the plasmid P0–3.9LacZ, which
contains a 4.3 kb Pax6 genomic sequence that includes the Pax6 lens ectoderm
enhancer, the Pax6 embryonic pancreatic enhancer, the Pax6 P0 promoter and a LacZ
reportergene (Zhanget al., 2002). Formapping thePax6pancreatic enhancer, a 1782bp
NsiI–XhoI fragment of theP0–3.9LacZvectorwas shortened to284bp (PCRamplified
using primers: 5′-TAAGATGCATGGCTACCGGGAGAACCTGACTCAGGC-3′
and 5′-AGCCCTCGAGCTTGTGCGGATCCCTGCAACCCAGC-3′); 237 bp
(PCR primers: 5′-CTTAATGCATGGTGACCCCAACGCCCGCTCCCTCTCGCC-
3′ and 5′-AGCCCTCGAGCTTGTGCGGATCCCTGCAACCCAGC-3′); 167 bp
(PCR primers: 5′-GAGCATGCATAAGCGTTGGCCTGGAGCTCGGGAGGGC-3′
and 5′-AGCCCTCGAGCTTGTGCGGATCCCTGCAACCCAGC-3′); or 246 bp
(PCR primers: 5′-TAAGATGCATGGCTACCGGGAGAACCTGACTCAGGC-3′
and 5′-TGCTCTCGAGCGAAGCTGGAAACGCCACAGCC-3′). For transgenic
constructsm5,mC,mR6 and Tg-con, the respective nucleotides weremodified using a
QuickChange site-directed mutagenesis kit (Stratagene) and verified by DNA
sequencing.
Mice
Transgenic mice were generated as described previously (Zhang et al.,
2002). Pbx1 and Pbx2 knockout mice are maintained in C57BL/6 and Black
Swiss background respectively (Capellini et al., 2006; Kim et al., 2002). We also
analyzed Pbx1 embryos from the original colony maintained by Dr. Michael
Cleary (Stanford University) and consistently observed a similar pancreatic
phenotype.
RT-PCR
Pancreatic tissue was dissected in ice-cold PBS and immediately placed in liquid
nitrogen. RNA was isolated from tissue extracts using a kit (RNA isolation kit,
Qiagen), and reverse transcription was carried out according to the manufacturer's
instructions (Invitrogen). The primers used for PCR are, Meis1 (forward: 5′-
AACCTCAACGCATCCGCAGGC-3′; reverse: 5′-GATTGACCAGTCAAATC-
GAGC-3′), Meis2 (forward: 5′-GGCATCCACTCGTTCAGGAGGA-3′, reverse:
5′-GATAGACCAGTCCAACCGAGC-3′), Meis3 (forward: 5′-CAGTGGTCTG-
TACATCTGGGG-3′, reverse: 5′-GATTGACCAGTCTAATCGCAC-3′), Prep1
(forward: 5′-CAGACTCAGCCCTACAACAGGG-3′, reverse: 5′-GCTTGATGC-
CAGCAACCCAGA-3′), Prep2 (forward: 5′-CAGCCTCAGCACTCCAG-
CAGGG-3′, reverse: 5′-GCTTGATGCCAGCAACCCAGA-3′).
EMSA
EMSAwas performed as described (Zhang et al., 2002). The probe for the
region containing the Meis–Pbx site in the wild-type Pax6 pancreatic element is
5′-GCCCTTTATTGACAGACAGATAGATAAGCTGG-3′. The consensus
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3′. The probes were made by annealing oligonucleotides of complementary
sequence. Antibodies for DNA binding interference assays were anti-Pbx1,
anti-Prep1 and anti-TGIF (all from Santa Cruz Biotechnology, Santa Cruz,
CA). Meis1, Meis2, Pbx1, Prep1 and Prep2 proteins were made by in vitro
transcription and translation using a kit (Promega). Expression vectors were
kindly provided by Dr. Neal Copeland (Meis1, Meis2) (NCI, Frederick), Dr.
Galvin Swift (Pbx1) (UT Southwestern, Dallas), Dr. Kenneth Gross (Prep1)
(Roswell Park Cancer Institute, Buffalo) and Dr. Mark Featherstone (Prep2)
(McGill Cancer Center, Montreal).
Histology, in situ hybridization and immunohistochemistry
X-gal staining, in situ hybridization and immunohistochemistry were
performed as previously described (Zhang et al., 2003). The following
antibodies were used: mouse anti-Pax6 and mouse anti-Islet-1 (Develop-
mental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), rabbit
anti-Pax6 (Covance, Berkeley, CA), mouse anti-insulin and rabbit anti-
glucagon (BioGenex, San Ramon, CA), guinea pig anti-Glucagon (Linco, St.
Charles, MO), rabbit anti-Meis1 and anti-Meis2 (kind gift from Dr. Arthur
Buchburg, Jefferson Medical College), rabbit anti-Pbx1/2/3 (Santa Cruz
Biotechnology, Santa Cruz, CA), rabbit anti-Pdx1 (kind gift from Dr. Chris
Wright, Vanderbilt University), rabbit anti-IDX-1 (kind gift from Dr. Joel
Habener, MGH, Harvard Medical School) and rabbit anti-Prep2 (kind gift
from Dr. Mark Featherstone, McGill Cancer Center). Rabbit and guinea pig
Prep1 antibodies were raised against the C-terminal 102 amino acids of
mouse Prep1 fused to GST using the expression vector pGEX-6P-3
(Amersham Bioscience). Both rabbit and guinea pig polyclonal antibodies
were raised by Covance and affinity-purified. The resulting anti-Prep1
antibodies were tested by Western blot and immunostaining and specifically
recognized Prep1 in transfected but not control cells.
To determine the Pax6/Pdx1 ratio, mouse embryos were sectioned serially
at 10 μm increments and stained with Pax6 and Pdx1 antibodies. The total
number of Pax6 and Pdx1 positive cells was counted on every 6th section for
E14.5 embryos or on at least 5 sections for E10.5 embryos. At least 3
embryos of each genotype were analyzed. The statistical significance was
calculated using Student's t test.Fig. 1. The minimal Pax6 pancreatic enhancer contains a conserved Meis–Pbx
site. (A) The Pax6 lens ectoderm enhancer (Lens), Pax6 embryonic pancreatic
enhancer (Pan) and the Pax6 P0 promoter are shown in the 3.9 kb Pax6
genomic sequence. The Meis–Pbx site lies at the beginning of the human/
mouse/fugu fish homologous region (the 5′ boundary denoted by a vertical line).
For transgenic analysis, the number of β-galactosidase expressing lines is shown
together with the total number of independent transgenic embryos. B: BamHI,
E: EcoRI, H: HindIII. (B) Transient transgenic embryos were collected at E10.5,
and the reporter gene activities in pancreas detected by X-gal staining (arrow).
Note that lens expression is preserved in each transgenic line, while truncation of
the minimal 237 bp element by 70 bp at the 5′-end (167 bp construct) or by
38 bp at the 3′-end (246 bp construct) results in loss of pancreatic expression.Results
The minimal Pax6 embryonic pancreatic enhancer contains a
composite Meis–Pbx binding site
To study the transcriptional regulation of Pax6, we first
determined the minimal sequence required for proper Pax6
pancreatic enhancer activity in transgenic mice. To do this, a
LacZ reporter gene was fused downstream of 4.3 kb of
murine Pax6 genomic sequence, containing the endogenous
Pax6 promoter (P0), the embryonic pancreatic enhancer
(Pan) and the lens ectoderm enhancer (Lens) (Zhang et al.,
2002). After two consecutive deletions to the previously
determined 450 bp Pax6 pancreatic enhancer element, the
resulting 237 bp sequence fully retained pancreatic expression
in all 5 E10.5 transgenic embryos analyzed (Figs. 1A, B).
Further deletion of 70 bp from the 5′ end or of 38 bp from the
3′ end of the 237 bp sequence, however, abolished all
pancreatic enhancer activity. This was not due to transgene
integration effects since lens expression was not affected.
Therefore, this 237 bp region is both necessary and sufficient
for Pax6 pancreatic enhancer activity. Comparison with the
genomes of mouse, human and Fugu fish revealed that,
although the 96 bp at the 3′ end of the enhancer is conservedbetween all three species, the 5′ portion of the 237 bp element
is homologous only between human and mouse. This suggests
the existence of mammalian specific regulatory elements that
control embryonic Pax6 pancreatic expression.
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revealed a perfect consensus Meis binding site (5′-TGA-
CAG-3′) at the 5′ end of homologous region between human,
mouse and Fugu fish (Chang et al., 1997; Shen et al., 1997)
(Fig. 1A). Consistent with evolutionary significance, this
Meis binding site is perfectly conserved between human,
mouse and fugu fish (Miles et al., 1998). This observation is
particularly intriguing in light of our previous finding that the
Pax6 embryonic lens enhancer also contains a Meis binding
site (5′-TGACAA-3′) and is regulated by Meis family
members (Zhang et al., 2002). In the developing lens, the
Meis protein forms a nuclear protein complex with additional
unknown co-factors to regulate Pax6 expression. Further
sequence analysis failed to identify any additional homology
between the lens and pancreatic Pax6 enhancers. However,
immediately downstream of the murine pancreatic Meis site is
a region (5′-AGATAGAT-3′) which closely resembles the
consensus Pbx binding site (5′-TGATTGAT-3′) (Van Dijk et
al., 1993) (Fig. 1A). In addition, previous studies have
established that Meis and Pbx can form functional hetero-
dimers and bind DNA synergistically (Berthelsen et al., 1998;
Chang et al., 1997), suggesting a model in which Meis and
Pbx cooperatively bind the Pax6 pancreatic enhancer to
regulate Pax6 expression.
Meis and Pbx family members are expressed throughout
pancreatic development
The vertebrate Meis family has five members, Meis1, Meis2,
Meis3, Prep1 and Prep2 (Berthelsen et al., 1998; Fognani et al.,
2002; Haller et al., 2002; Moskow et al., 1995; Nakamura et al.,
1996). These proteins all contain an N-terminal Meis domain,
which mediates the interaction with Pbx, and a C-terminal
homeodomain that can bind DNA. To determine whether Meis
family members are expressed in the pancreas, we first
performed RT-PCR to examine Meis transcripts in the whole
pancreas. In both postnatal day P3 and adult pancreata, Meis1,
Meis2 and Prep1 were clearly expressed (Fig. 2A). In
embryonic E14.5 pancreata, transcripts of all five Meis family
genes were detected (Fig. 2A). Consistent with this finding, we
also observed Meis1, Meis2, Prep1 and Prep2 protein
expression in the developing E10.5 pancreas by immunostain-
ing (Figs. 2B–E). The antibodies used were specific to each of
the four proteins, as demonstrated by their unique staining
patterns in the spinal cord (data not shown). At E10.5, Meis1
and Meis2 were strongly expressed in pancreatic mesenchyme
and only weakly co-localized with scattered Pax6 positive
pancreatic epithelial cells (Figs. 2B, C). In contrast, Prep1
protein was ubiquitously expressed in pancreatic epithelial
cells, thus overlapping with Pax6 positive cells (Fig. 2D). Prep2
showed strong pancreatic mesenchymal expression, but also co-
localized with Pax6 positive epithelial cells (Fig. 2E). These
results were further confirmed by RNA in situ hybridization
(data not shown).
We next examined Pbx gene expression in the E10.5
pancreas. Adjacent pancreatic sections from E10.5 embryos
were analyzed for Pax6, Pbx1, Pbx2 and Pbx3 transcripts byRNA in situ hybridization and for total Pbx protein by
immunofluorescence with a pan-Pbx reactive antibody (Figs.
2F–I). While Pax6 was detected only in clusters of islet cells at
this stage (Fig. 2F), Pbx1 and Pbx2 were widely expressed in
the pancreatic region (Figs. 2G, H). Pbx1 expression was
detected at high levels in pancreatic mesenchyme and apparent
only at lower levels in pancreatic epithelium (Fig. 2G). Pbx2
was expressed in both the epithelial and mesenchymal
compartments (Fig. 2H), while Pbx3 pancreatic expression
was not detected at this stage by this method (data not shown).
Consistent with these results, a pan-Pbx antibody detected
expression of Pbx proteins in both pancreatic epithelial and
mesenchymal cells, and a subset of Pbx positive epithelial cells
co-expressed Pax6 (Fig. 2I). Prior studies have also detected
Pbx1 and Pbx3 expression in developing islet cells (Gu et al.,
2004; Kim et al., 2002). Taken together, we conclude that Pax6,
Meis and Pbx family members exhibit overlapping expression
in the developing endocrine pancreas.
Prep1 and Pbx1 bind the Pax6 pancreatic enhancer
synergistically
Our previous studies indicated that both Meis1 and Meis2
have the potential to regulate Pax6 expression in the lens
(Zhang et al., 2002). We thus performed DNA electrophoretic
mobility shift assays (EMSAs) to test whether these two
proteins could also bind the Pax6 pancreatic enhancer element.
Interestingly, neither Meis1, Meis2 nor Pbx1 (lane 4) alone
bound a 26 bp oligonucleotide containing the putative Meis–
Pbx site (Fig. 3 and data not shown). However, inclusion of both
Meis1 and Pbx1 (lane 2) or Meis2 and Pbx1 (lane 3) proteins in
the EMSA resulted in a moderately abundant shift in DNA
mobility, indicating the formation of binary protein complexes
on the DNA (Fig. 3). Moreover, the synergistic binding between
Meis1 or 2 and Pbx1 was abolished by an anti-Pbx antibody but
not by a control anti-Prep1 antibody (data not shown). Thus,
Meis1 or 2 and Pbx1 cooperatively bind the Pax6 pancreatic
enhancer in vitro.
We next tested the DNA binding activity of Prep1. While
both Meis1 and Meis2 bound the Pax6 enhancer element in
conjunction with Pbx1, a markedly stronger binding was
observed when Prep1 and Pbx1 were tested together (Fig. 3,
lane 6 vs. lanes 4 and 5). The Prep1–Pbx1 complex was
sensitive to antibodies against Prep1 or Pbx (lanes 7 and 8), but
not to a control anti-TGIF antibody (lane 9; TGIF is another
closely related TALE family homeoprotein). Similarly, we also
observed strong cooperative binding of Prep2 and Pbx1 to the
26 bp probe (data not shown). The differential binding affinities
exhibited by Meis1, Meis2, Prep1 and Prep2 are surprising
because PCR-based binding site selection experiments suggest
that Meis1 and Prep1 prefer identical consensus sequences
(Berthelsen et al., 1998; Chang et al., 1997). Indeed, Meis1,
Meis2 and Prep1 also bound equally strongly with Pbx1 protein
on a probe containing a Meis–Pbx composite site (5′-
TGATTAGCAG-3′) taken from the literature (Fig. 3; lanes
11, 12 and 15) (Chang et al., 1997). Therefore, the preferential
binding of Prep1 and Pbx1 or of Prep2 and Pbx1 to the Pax6
Fig. 2. Expression analysis of Meis and Pbx family members during pancreatic development. (A) RT-PCR analysis was carried out for adult, day P3 and E14.5 mouse
pancreas. In the adult and P3 pancreas, Meis1, Meis2 and Prep1 are expressed. In E14.5 pancreata, all 5 Meis family genes were detected. Pax6, β-actin and ribosomal
L19 transcripts were present in all three samples. The nominally equivalent efficiencies of the PCR primers for the different Meis family genes were established by
testing equal amounts of plasmid DNA for each gene as template (data not shown). (B–E) At E10.5, immunohistochemistry detected Meis1 and Meis2 proteins mainly
in pancreatic mesenchyme, while Prep1 and Prep2 proteins are present throughout the pancreas and co-localize with Pax6 in islet cells (yellow nuclei). (F–G) Pax6,
Pbx1 and Pbx2 transcripts and protein detected by RNA in situ hybridization and immunohistochemistry. Circled regions depict the boundary of the pancreatic
epithelium containing prospective islet cells. Pbx1 expressed is detected at higher levels in pancreatic mesenchyme relative to epithelium, whereas Pbx2 is expressed in
both compartments. The pan-Pbx antibody detects co-expression of Pax6 (red fluorophore) and Pbx (green fluorophore) in islet cells (yellow nuclei).
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element, and not to a difference in protein concentrations or
activities. Especially when taken with the results from preceding
expression experiments, these results strongly suggest that Prep1
and Prep2 are the most likely Meis family candidates to be in-
volved in regulation of the Pax6 embryonic pancreatic enhancer.
Mutational analysis of the Meis–Pbx site
We next undertook an in vitro mutational analysis of the
Prep1 and Pbx1 composite binding site in the Pax6 pancreatic
enhancer sequence (Fig. 4A). In EMSAs, whereas mutation of 2
bases 5′ to the Meis site did not affect Prep1–Pbx1 binding,
replacement of 5 of the 6 bases of the Meis binding site (mutant
C) completely abolished complex formation in vitro (Fig. 4B
and data not shown). Moreover, as further evidence that the
Meis site is required for Prep1–Pbx1 binding, point mutations(mutant m5 and mutant m1) within the Meis site significantly
inhibited protein–DNA complex formation (Fig. 4B).
In the 8 bp Pbx site, mutation of 2 bases (mutant R2), 4 bases
(mutant R4) or 6 bases (mutant mR6) progressively reduced the
binding affinity of the Prep1–Pbx1 complex to DNA (Fig. 4C).
However, deletion from the probe of all 8 bases comprising the
Pbx1 site (mutant RΔ) did not abolish complex binding, which
is thus relatively independent of the sequence of the Pbx site
(Fig. 4C). This finding is surprising considering that Pbx1
protein is critically required for Prep1 to bind to the Pax6
pancreatic enhancer (see Fig. 3) and suggests that Pbx1
contributes to the stability of the binding complex by inducing
a conformational change in Prep1. Lastly, we replaced the Pbx
site in the Pax6 pancreatic enhancer with a consensus Pbx
binding sequence (mutant Rc); this led to the expected result of
stronger Prep1–Pbx1 binding (Fig. 4C). The protein–DNA
complex on RΔ and Rc probes was abolished in the presence of
Fig. 4. Meis and Pbx sites are required for Prep1 and Pbx1 binding and
transactivation. (A) Sequences of Meis and Pbx site mutations. (B) Mutations in
Meis sites disrupt the binding activity of Prep1 and Pbx1 in EMSA. Note that
mutant mC completely abolishes Prep1 and Pbx1 binding. (C) Mutations in Pbx
sites weaken Prep1/Pbx1 binding. (D) Protein complexes that form on RΔ and
Rc are sensitive to Prep1 and Pbx1 antibodies.
Fig. 3. Prep and Pbx proteins preferentially bind to the Pax6 pancreatic
enhancer. Probes containing the wild-type Meis–Pbx site in the Pax6 pancreatic
enhancer (Wild Type) form complexes with either Meis1 and Pbx1, or Meis2
and Pbx1, but not with Meis1, Meis2, Prep1 or Pbx1 individually. Much
stronger binding is observed for the Prep1 and Pbx1 complex, whose formation
is blocked by anti-Pbx1 or anti-Prep1 antibodies, but not by anti-TGIF antibody.
For the consensus Meis–Pbx probe (Consensus), equally strong Meis1–Pbx1,
Meis2–Pbx2 and Prep1–Pbx1 binding is observed, validating the protein
activities in the experiments employing the wild-type probe.
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protein complexes indeed consisted of Prep1 and Pbx1 (Fig.
4D). In summary, both the Meis and Pbx sites in the Pax6
pancreatic enhancer contribute to the stabilization of a Prep1–
Pbx1 complex on DNA.
Pax6 pancreatic enhancer activity in mice requires a functional
Meis–Pbx site
Although we identified several pancreatic endocrine cell
lines that expressed Meis1, Meis2, Prep1 and Pax6, none
supported the activity of the Pax6 pancreatic enhancer upon
transfection. Not surprisingly, we found that neither Prep1–
Pbx1 nor Meis1–Pbx1 transactivates the Pax6 pancreatic
enhancer in any of these cell culture systems (data not shown).
To test the functional requirement of the Meis–Pbx site for
Pax6 pancreatic enhancer activity during development, we
performed mutational analyses in transgenic mice. We
employed constructs containing both the Pax6 pancreatic and
lens enhancers, so that lens expression could serve as an internal
standard for changes in pancreatic expression. When a single
base mutation in the Meis site (mutant m5) was introduced into
construct P0–3.9LacZ in transgenic mice, pancreatic expression
was significantly reduced in all 11 independent lacZ reporter
expressing lines (Figs. 5A, B). Additionally, mutation of 5 bases
in the Meis site (mutant mC) completely abolished enhancer
activity in the pancreas in all 5 expressing lines (Fig. 5). Incontrast, lens expression of the two mutant transgenic constructs
was at least as strong as that of the wild-type transgene. Thus,
the in vivo effects of Meis site mutations on Pax6 pancreatic
enhancer activity directly correlate with the effects of these
mutations on Prep1–Pbx1 DNA binding in vitro.
We next tested the effect of a 6-base mutation in the Pbx site
(mutant mR6). In contrast to the wild-type transgene, this
mutation reduced but did not abolish pancreatic enhancer
activity in all 9 independent lines assayed. This result is
consistent with the biochemical experiment which produced a
similar result (see Fig. 4B). Taken together, these results support
the hypothesis that both Meis and Pbx sites are required for
optimal transcriptional activity of the Pax6 pancreatic enhancer.
Meis and Pbx bind the Pax6 pancreatic enhancer in a
relatively weak manner compared to their binding to the
consensus composite Meis–Pbx site described in the literature.
This observation raises the question of whether the endogenous
Pax6 enhancer sequence, which deviates from the consensus
both in sequence and in the relative orientation of the Meis and
Pbx sites, is functionally equivalent to the consensus sequence
(Fig. 5A). To address this question, we replaced the 16 bp
Fig. 5. The Meis–Pbx site is required for Pax6 pancreatic enhancer activity in
transgenic mice. (A) Schematic diagram of the transgenic constructs. The Meis
and Pbx sites and the mutants tested are highlighted. (B) Representative E10.5
transgenic embryos carrying the designated transgenes. Note that, whereas lens
expression is preserved, pancreatic expression is diminished in mutant embryos
containing the m5, mC and mR6 constructs (arrows). Replacement of the wild-
type Meis–Pbx sequence with the consensus sequence (Tg-con) results in
retention of transgene expression in the pancreas (con). *Weak pancreatic
expression was detectable in the m5 and mR6 embryos.
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construct with a 10 bp Meis–Pbx consensus sequence (Tg-con)
taken from the literature (Chang et al., 1997) and then assayed
LacZ reporter activity of the Tg-con transgene in transgenic
mice at E10.5. Pancreatic expression similar to that seen with
the Pax6 pancreatic enhancer was observed in 4 out of 4 of
these Tg-con transgenics. In addition, immunohistochemistry
showed co-localization of the LacZ and Pax6 expressing cells
in the E10.5 pancreas (Fig. 5B). Therefore, during early
embryonic development, a Meis–Pbx consensus sequence can
functionally substitute for an indispensable region of the Pax6
pancreatic enhancer.
Pax6 is down-regulated in the Pbx1 and Pbx2 knockout
pancreas
To test whether Pbx1 is required for Pax6 pancreatic
expression, we first re-examined pancreatic development in
Pbx1 deficient mouse embryos (Kim et al., 2002). At E14.5, the
number of Pax6 expressing cells and their qualitative intensitywere strongly reduced in E14.5 Pbx1 mutants. This was in
contrast to the robust expression of Pdx1 found in Pbx1 mutant
pancreatic epithelium, suggesting that Pax6 down-regulation is
not due to general deficiency of pancreatic progenitors (Fig.
6A). Indeed, the ratio of Pax6/Pdx1 positive cells was
significantly reduced in Pbx1 mutant embryos (Fig. 6D).
Endocrine cell differentiation defects in Pbx1mutants were also
revealed by decreased insulin and glucagon expression, as well
as by a reduction in the number of Islet-1 positive cells (Fig. 6A
and data not shown). These results confirm a previous
demonstration that Pbx1 is required for proper pancreatic
development (Kim et al., 2002) but additionally demonstrate
that Pbx1 is required at 14.5 for the maintenance of pancreatic
Pax6 expression.
We next analyzed Pax6 pancreatic expression in E10.5 Pbx1
mutants. Strong expression of Pax6, glucagon, islet-1 and Pdx1
was detected in both wild-type and Pbx1 mutant pancreatic
epithelium, and the Pax6/Pdx1 cell number ratio was unchanged
(Figs. 6B–D and data now shown). This demonstrates that islet
cell differentiation is not significantly disrupted by Pbx1
mutation during early pancreatic development. In E10.5
Pbx1−/−Pbx2+/− compound embryos, however, we observed
severe pancreatic hypoplasia and significant reduction in the
number of Pax6 positive cells and Pax6/Pdx1 ratio (Figs. 6C,
D). More importantly, the level of Pax6 expression in the
remaining endocrine cells was also down-regulated. This was
shown more clearly by RNA in situ hybridization, which
revealed that Pax6 expression was lower in Pbx1−/−Pbx2+/−
pancreatic buds than in wild-type controls (Fig. 6C). As control,
Pax6 expression in the neural tube remained unchanged in the
Pbx1−/−Pbx2+/− mutants. Therefore, Pbx1 and Pbx2 together
regulate Pax6 expression during early pancreatic development.
Discussion
Role of Meis family members
In this paper, we have defined a minimal 237 bp enhancer for
embryonic Pax6 pancreatic expression. Transgenic experiments
further demonstrate that the Meis–Pbx binding site in this
enhancer is critical for its activity and that a Meis–Pbx
consensus sequence can substitute for the endogenous binding
site in this regard. We also show that the Meis and Pbx family
members, Prep1 and Pbx1 respectively, can bind this element
cooperatively. It is likely that other Meis and Pbx family
members, such as Prep2 and Pbx2, can also bind this element
cooperatively. We found that Prep2 acted interchangeably with
Prep1 in EMSA (data not shown), and based on sequence
similarity, Pbx2 should act similarly to Pbx1. Moreover, both
Prep2 and Pbx2 share co-expression with Pax6 in the
developing pancreatic epithelium at E10.5, when the enhancer
is active. Many Meis and Pbx family members are expressed
during pancreatic development, and members of each family
recognize closely related DNA sequences. However, we
observed that the Meis family members Prep1 and Prep2 form
substantially stronger binding complexes with Pbx1 on the
Pax6 pancreatic enhancer than do Meis1 and Meis2. These
Fig. 6. Pax6 expression is reduced in Pbx1 and Pbx2 mutant pancreata. (A) In E14.5 Pbx1 mutant pancreata, marked reductions in Pax6, Islet-1, glucagon and insulin
expression are observed. However, Pdx1 expression remains relatively unchanged. (B) Pax6 and glucagon are expressed in E10.5 Pbx1 mutant pancreata, but down-
regulated in Pbx1−/−Pbx2+/−mutants. The pancreatic epithelium is marked by strong Pdx1 protein expression and outlined with dotted lines. (C) Pax6mRNA level in
the pancreas is reduced in E10.5 Pbx1−/−/Pbx2+/− mutant as shown by RNA in situ hybridization. The same pancreas section was stained for glucagon to mark alpha
cells. Pax6 expression in the neural tube on the same sections is not changed. (D) Quantification of E10.5 and E14.5 Pax6+/Pdx1+ cell ratios. Specific loss of Pax6
expressing cells is observed in Pbx1−/− mutants at E14.5 and Pbx1−/−Pbx2+/− mutants at E10.5.
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among Meis family proteins and, taken with their co-
localization with Pax6, suggest that Prep1 and Prep2 are the
most critical Meis factors regulating Pax6 during pancreatic
development. Further analysis of Prep1 and Prep2 mutant mice
should clarify the role of these genes in Pax6 embryonic
pancreatic expression.
Role of Pbx family members
Previous studies have identified an important role for Pbx1
in pancreas development. Genetic ablation of Pbx1 results in
severe pancreatic hypoplasia and β cell dysfunction (Kim et al.,
2002). Consistent with this phenotype, binding sites for Pbx1
and its co-factors, Pdx1 and Meis/Prep family proteins, have
been found in both endocrine and exocrine genes, including
somatostatin, glucagon and elastase (Herzig et al., 2000; Peers
et al., 1995; Swift et al., 1998). In addition, Pbx1 and Pdx1
genetically interact in glucose homeostasis, and a Pdx1 mutant
lacking Pbx1 binding ability fails to support the normal
migration and proliferation of pancreatic islet cells (Dutta et
al., 2001; Kim et al., 2002). Therefore, Pbx1, together with Meis
and Pdx1, directly regulates β cell function in the pancreas.
Nevertheless, study of Pbx1 knockout mice has also shown thatPbx1 is required for both endocrine and exocrine cell
differentiation, suggesting that Pbx1 also regulates pancreatic
developmental genes. In this study, we present biochemical and
transgenic data showing that the critical developmental
regulatory gene Pax6 is a direct target of Pbx1 during islet
genesis. Thus, Pbx1 acts at multiple levels during pancreas
development.
The analysis of Pbx1–Pbx2 compound knockout embryos
also demonstrates that both Pbx1 and Pbx2 are required for
Pax6 regulation. In E14.5 Pbx1 mutant pancreatic islets, we
observed significant reductions in the number of Pax6 positive
cells relative to the number of Pdx1 positive cells; this was also
accompanied by a down-regulation in insulin and glucagon.
Although we found little change in Pax6 expression in Pbx1
mutant pancreatic epithelium at E10.5, in Pbx1−/−Pbx2+/−
mutants, we observed a significant loss of Pax6 positive cells in
the pancreatic bud. Moreover, Pax6 transcript levels in islet
progenitors were also much reduced. Since Pbx1/2 inactivation
leads to profound pancreatic defects, we cannot rule out the
possibility that the loss of Pax6 expression is due to pleiotropic
effects of the Pbx1/2 mutation on pancreatic development.
However, the reduction of Pax6 mRNA levels shows that Pbx1
and Pbx2 must regulate Pax6 at the transcriptional level. Thus,
our results are consistent with a model whereby Pax6 is a direct
756 X. Zhang et al. / Developmental Biology 300 (2006) 748–757downstream target of Pbx1, Pbx2 or both in pancreatic
development. In addition, although we were unable to detect
Pbx3 expression in the E10.5 pancreas by whole mount in
situ hybridization, Pbx3 has been detected in Pdx1 positive cells
in microarray studies (Table S4 in Gu et al., 2004) and also at
later stages of pancreatic development (Di Giacomo et al., in
press). Of note, while transgenic analysis demonstrates the
critical importance of the Meis–Pbx binding site for endogen-
ous Pax6 pancreatic enhancer activity, Pax6 expression is not
completely eliminated in Pbx1−/−Pbx2+/− compound mutant
embryos. This discrepancy could be accounted for by genetic
redundancy from the remaining copy of Pbx2 or by a different
Pbx gene family during pancreatic epithelial development.
Thus, in principle, all three Pbx genes may contribute to the
regulation of Pax6 pancreatic expression.
Conserved role for Meis in Pax6 regulation
We previously showed that Meis1 and Meis2 are direct
upstream regulators of Pax6 in vertebrate lens development
where they act upon a Meis site juxtaposed to a non-Pbx co-
factor site in the Pax6 lens placode enhancer (Zhang et al.,
2002). In this paper, we have extended the requirement for a
Meis-site-dependent regulatory mechanism to embryonic Pax6
pancreatic expression. It is notable that, although the Pax6 lens
and pancreatic enhancers share Meis binding sites, the Meis co-
factors that bind these two elements are likely different. In the
Pax6 pancreatic enhancer, Pbx protein is the requisite binding
partner of Meis, but in the Pax6 lens enhancer, Pbx does not
bind DNA even in the presence of Meis protein. Not
surprisingly, therefore, inactivation of Pbx1 disrupts Pax6
expression in the pancreas but not in the lens (this paper and
data not shown). In fact, the Pax6 lens and pancreatic enhancers
do not share any other apparent homologous sequence except
their respective Meis sites. This suggests that Meis may interact
with different sets of transcription factors in lens and pancreas.
Therefore, the conserved regulation of Pax6 by Meis proteins
may be accomplished in different organs by changes in the
identities of the Meis co-factors, which may then further define
the different tissue-specific activities of these enhancers.
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